Search research articles
Contact Us
Filters
Showing results (81-90 of 133) with videos related to
Page
of 14
Sort By:
Investigational New Drugs
|
December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
Cancer Cell
|
October 10, 2018
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis
William B Tu, Yu-Jia Shiah, Corey Lourenco, et al.
Breast Cancer Research and Treatment
|
November 28, 2017
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
Rossanna C Pezo, Tom W Chen, Hal K Berman, et al.
Nature Communications
|
February 21, 2025
Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay
Mitchell J Elliott, Philippe Echelard, Christodoulos Pipinikas, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
Jeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.
NPJ Precision Oncology
|
June 3, 2026
Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer
Christopher Pretz, Jesús Fuentes-Antrás, Sasha Main, et al.
The New England Journal of Medicine
|
July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, Hope S Rugo, David W Cescon, et al.
Cancer Gene Therapy
|
August 23, 2024
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification
Christopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, et al.
Journal of the National Cancer Institute
|
December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
David W Cescon, Peter Schmid, Hope S Rugo, et al.
NPJ Breast Cancer
|
September 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Seock-Ah Im, Javier Cortes, David W Cescon, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 133) with videos related to
Sort By:
Page
of 14
Investigational New Drugs
|
December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
Cancer Cell
|
October 10, 2018
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis
William B Tu, Yu-Jia Shiah, Corey Lourenco, et al.
Breast Cancer Research and Treatment
|
November 28, 2017
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
Rossanna C Pezo, Tom W Chen, Hal K Berman, et al.
Nature Communications
|
February 21, 2025
Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay
Mitchell J Elliott, Philippe Echelard, Christodoulos Pipinikas, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
Jeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.
NPJ Precision Oncology
|
June 3, 2026
Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer
Christopher Pretz, Jesús Fuentes-Antrás, Sasha Main, et al.
The New England Journal of Medicine
|
July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, Hope S Rugo, David W Cescon, et al.
Cancer Gene Therapy
|
August 23, 2024
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification
Christopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, et al.
Journal of the National Cancer Institute
|
December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
David W Cescon, Peter Schmid, Hope S Rugo, et al.
NPJ Breast Cancer
|
September 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Seock-Ah Im, Javier Cortes, David W Cescon, et al.
Page
of 14